We found that puerarin works by regulating the FMO5/PPARα signaling pathway, providing a promising experimental basis for the potential therapeutic application of puerarin in preventing NAFLD. This evidence concerns the gene FMO5 and metabolic dysfunction-associated steatotic liver disease.